|
1) Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost. 2004; 30: 95-108
|
|
|
|
2) Sierko E, Wojtukiewicz MZ. Inhibition of platelet function: does it offer a chance of better cancer progression control？ Semin Thromb Hemost. 2007; 33: 712-21
|
|
|
|
|
|
3) Estrov Z, Talpaz M, Mavligit G, et al. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med. 1995; 98: 551-8
|
|
|
|
|
|
4) Gastl G, Plante M, Finstad CL, et al. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol. 1993; 83: 433-41
|
|
|
|
|
|
5) Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A. 1968; 61: 46-52
|
|
|
|
|
|
6) Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost. 1995; 74: 282-90
|
|
|
|
|
|
7) Tsuruo T, Fujita N. Platelet aggregation in the formation of tumor metastasis. Proc Jpn Acad Ser B Phys Biol Sci. 2008; 84: 189-98
|
|
|
|
|
8) Nieswandt B, Hafner M, Echtenacher B, et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999; 59: 1295-300
|
|
|
|
|
|
9) Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor？ Blood. 2003; 102: 449-61
|
|
|
|
|
|
10) Kitagawa H, Yamamoto N, Yamamoto K, et al. Involvement of platelet membrane glycoprotein Ib and glycoprotein IIb/IIIa complex in thrombin-dependent and- independent platelet aggregations induced by tumor cells. Cancer Res. 1989; 49: 537-41
|
|
|
|
|
|
11) Holme R, Oftebro R, Hovig T. In vitro interaction between cultured cells and human blood platelets. Thromb Haemost. 1978; 40: 89-102
|
|
|
|
|
|
12) Gasic GJ, Gasic TB, Jimenez SA. Effects of trypsin on the platelet-aggregating activity of mouse tumor cells. Thromb Res. 1977; 10: 33-45
|
|
|
|
|
|
13) Katagiri Y, Hayashi Y, Baba I, et al. Characterization of platelet aggregation induced by the human melanoma cell line HMV-I: roles of heparin, plasma adhesive proteins, and tumor cell membrane proteins. Cancer Res. 1991; 51: 1286-93
|
|
|
|
|
|
14) Watanabe M, Okochi E, Sugimoto Y, et al. Identification of a platelet-aggregating factor of murine colon adenocarcinoma 26: Mr 44, 000 membrane protein as determined by monoclonal antibodies. Cancer Res. 1988; 48: 6411-6
|
|
|
|
|
|
15) Kato Y, Fujita N, Kunita A, et al. Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem. 2003; 278: 51599-605
|
|
|
|
|
|
16) Mishima K, Kato Y, Kaneko MK, et al. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. 2006; 111: 483-8
|
|
|
|
|
|
17) Suzuki-Inoue K, Kato Y, Inoue O, et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem. 2007; 282: 25993-6001
|
|
|
|
|
|
18) Timar J, Tovari J, Raso E, et al. Platelet-mimicry of cancer cells: epiphenomenon with clinical significance. Oncology. 2005; 69: 185-201
|
|
|
|
|
|
19) Oleksowicz L, Mrowiec Z, Schwartz E, et al. Characterization of tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. Thromb Res. 1995; 79: 261-74
|
|
|
|
|
|
20) Kim YJ, Borsig L, Varki NM, et al. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A. 1998; 95: 9325-30
|
|
|
|
|
|
21) Borsig L, Wong R, Feramisco J, et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A. 2001; 98: 3352-7
|
|
|
|
|
|
22) Ludwig RJ, Boehme B, Podda M, et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 2004; 64: 2743-50
|
|
|
|
|
|
23) Hostettler N, Naggi A, Torri G, et al. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J. 2007; 21: 3562-72
|
|
|
|
|
|
24) Jain S, Zuka M, Liu J, et al. Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci U S A. 2007; 104: 9024-8
|
|
|
|
|
|
25) Terraube V, Pendu R, Baruch D, et al. Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost. 2006; 4: 519-26
|
|
|
|
|
|
26) Kisucka J, Butterfield CE, Duda DG, et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A. 2006; 103: 855-60
|
|
|
|
|
|
27) Clezardin P, Drouin J, Morel-Kopp MC, et al. Role of platelet membrane glycoproteins Ib/IX and IIb/IIIa, and of platelet alpha-granule proteins in platelet aggregation induced by human osteosarcoma cells. Cancer Res. 1993; 53: 4695-700
|
|
|
|
|
|
28) Bakewell SJ, Nestor P, Prasad S, et al. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A. 2003; 100: 14205-10
|
|
|
|
|
|
29) Camerer E, Qazi AA, Duong DN, et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood. 2004; 104: 397-401
|
|
|
|
|
|
30) Costantini V, Zacharski LR. Fibrin and cancer. Thromb Haemost. 1993; 69: 406-14
|
|
|
|
|
|
31) Suzuki-Inoue K, Fuller GL, Garcia A, et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood. 2006; 107: 542-9
|
|
|
|
|
|
32) Kato Y, Kaneko MK, Kunita A, et al. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci. 2008; 99: 54-61
|
|
|
|
|
|
33) Boucharaba A, Serre CM, Gres S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest. 2004; 114: 1714-25
|
|
|
|
|
|
34) Salgado R, Vermeulen PB, Benoy I, et al. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer. 1999; 80: 892-7
|
|
|
|
|
|
35) Benoy I, Salgado R, Colpaert C, et al. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer. 2002; 2: 311-5
|
|
|
|
|
|
36) Kim HK, Song KS, Park YS, et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer. 2003; 39: 184-91
|
|
|
|
|
|
37) Verheul HM, Jorna AS, Hoekman K, et al. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood. 2000; 96: 4216-21
|
|
|
|
|
|
38) Janowska-Wieczorek A, Wysoczynski M, Kijowski J, et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer. 2005; 113: 752-60
|
|
|
|
|
|
39) Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, et al. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion. 2006; 46: 1199-209
|
|
|
|
|
|
40) Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther. 2008; 8: 1247-55
|
|
|
|
|
|
41) Amirkhosravi A, Mousa SA, Amaya M, et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost. 2003; 90: 549-54
|
|
|
|
|